ProShare Advisors
AVBP icon

ProShare Advisors’s ArriVent BioPharma AVBP Stock Holding History

ProShare Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+6,491
New +$192K ﹤0.01% 1574
2025
Q1 		– Sell
-9,532
Closed -$254K – 2256
2024
Q4 		$254K Buy
+9,532
New +$274K ﹤0.01% 1756

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ProShare Advisors's AVBP Position: Q2 2026 in Review

ProShare Advisors opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 6,491 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #1574 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in AVBP as recently as Q4 2024.

ProShare Advisors first reported a position in AVBP in Q4 2024 and has held it in 2 quarters since. The position peaked at $254K in Q4 2024. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • ProShare Advisors held 6,491 shares of ArriVent BioPharma worth $225K as of Q2 2026.
  • ArriVent BioPharma was a new ProShare Advisors position in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1574 holding.
  • ProShare Advisors first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 2 quarters since.
  • ProShare Advisors's ArriVent BioPharma position peaked at $254K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.